Difference between revisions of "Ticagrelor (Brilinta)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "Category:Drug index" to "Category:Drugs")
m
 
(3 intermediate revisions by 2 users not shown)
Line 4: Line 4:
 
<br>Extravasation: n/a
 
<br>Extravasation: n/a
  
=History of changes in FDA indication=
+
==History of changes in FDA indication==
 
'''Note that this agent does not have a hematology-specific indication at this time.'''
 
'''Note that this agent does not have a hematology-specific indication at this time.'''
*7/20/2011: Initial FDA approval to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) (unstable angina, non-ST elevation myocardial infarction, or ST elevation myocardial infarction).
+
*2011-07-20: Initial approval to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) (unstable angina, non-ST elevation myocardial infarction, or ST elevation myocardial infarction).
*9/3/2015: Indication revised to reduce the rate of cardiovascular death, myocardial infarction, and stroke in patients with acute Guide coronary syndrome (ACS) or a history of myocardial infarction (MI).
+
*2015-09-03: Indication revised to reduce the rate of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI).
 +
 
 +
==Also known as==
 +
*'''Brand names:''' Brilinta, Brilique, Ticalog
  
 
[[Category:Drugs]]
 
[[Category:Drugs]]
Line 14: Line 17:
 
[[Category:P2Y12 ADP inhibitors]]
 
[[Category:P2Y12 ADP inhibitors]]
  
[[Category:Drugs FDA approved in 2011]]
+
[[Category:FDA approved in 2011]]

Latest revision as of 13:17, 9 May 2023

General information

Class/mechanism: Reversible cyclopentyl-triazolo-pyrimidine class inhibitor of the P2Y12 class of adenosine diphosphate (ADP) receptors on platelets, inhibiting platelet activation and aggregation.
Route: PO
Extravasation: n/a

History of changes in FDA indication

Note that this agent does not have a hematology-specific indication at this time.

  • 2011-07-20: Initial approval to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) (unstable angina, non-ST elevation myocardial infarction, or ST elevation myocardial infarction).
  • 2015-09-03: Indication revised to reduce the rate of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI).

Also known as

  • Brand names: Brilinta, Brilique, Ticalog